公开(公告)号：US20060183122A1

公开(公告)日：2006-08-17

申请号：US10540904

申请日：2003-12-26

申请人： Scott Kern ,  Michael Van Der Heijden

发明人： Scott Kern ,  Michael Van Der Heijden

IPC分类号： C12Q1/68

CPC分类号： C07K14/47 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156

摘要： The present invention relates to methods of determining if a patient has cancer or is at increased risk of developing cancer, particularly pancreatic cancer, the method comprising testing a FANC gene for the presence of a cancer-associated coding change, wherein said presence of one or more cancer-associated coding changes is indicative of cancer or an increased risk of cancer in said patient. The invention further relates to methods of treating a patient having cancer, particularly pancreatic cancer, who has one or more cancer-associated coding changes in the FANC genes comprising the step of administering a therapeutically effective amount of a chemotherapeutic cross-linking agent.

摘要翻译： 本发明涉及确定患者是否患有癌症或具有发展为癌症，特别是胰腺癌的风险增加的方法，所述方法包括测试FANC基因以存在癌症相关编码变化，其中所述存在一种或多种 更多的癌症相关的编码变化是所述患者中的癌症或增加的癌症风险的指示。 本发明还涉及治疗患有癌症的患者，特别是胰腺癌的方法，所述患者在FANC基因中具有一种或多种与癌症相关的编码变化，包括给予治疗有效量的化学治疗性交联剂的步骤。